CAR-T therapy will eventually replace stem cell treatments as the standard treatment for Hodgkin’s lymphoma, analysts have predicted.
The US Food and Drug Administration have designated a new CAR-T cell therapy for Hodgkin’s lymphoma as a “regenerative medicine advanced therapy,” the first time this has been awarded to CAR-T cell treatment.
The treatment TT11, developed by Tessa Therapeutics, is currently the only Hodgkin’s CAR-T treatment at an advanced stage of clinical testing. The manufacturers say it has achieved a response rate of 66.7% in patients have failed other attempts of treatment.
TT11 still needs full regulatory approval, but according to analysts at GlobalData, developers may be able to demonstrate surrogate endpoints to support an application. Tessa Therapeutics hope to commence a multi-site phase II trial later in 2020.
Oncology and haematology analyst Miguel Ferreira from GlobalData said: “The current landscape of second-line treatment in Hodgkin’s lymphoma is only partially set in stone. Salvage treatment and stem cell transplants are the standard of care, though the toxicity and impact on quality of life of patients labels this approach as outdated and highly toxic despite response benefit.
“A new treatment that can displace or replace stem cell transplants to improve the response, quality of life as well as treatable population in Hodgkin’s lymphoma second line has been highly anticipated.”
Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.
News service provided by Englemed News http://www.englemed.co.uk/